BCL2 and ovarian carcinoma: Since COMMD1 inhibits NF-κB activity and can interact with BRCA1, it is tempting to speculate that nuclear COMMD1 represses the BRCA1-p50 mediated transcription of BCL2 and XIAP and thereby sensitizes ovarian cancer cells to cisplatin-induced apoptosis (model in Fig 6).